Anticoagulants Market Size & Share 2023 to 2032
Market Size by Drug Class (Factor Xa Inhibitors, Heparin), Route of Administration (Oral, Injectables), Application (Thromboembolism, Atrial Fibrillation, Coronary Artery Disease), Distribution Channel & Global Forecast.
Report ID: GMI4967
|
Published Date: June 2023
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
Anticoagulants Market Size
Anticoagulants Market size accounted for more than USD 39.2 billion in 2022 and is estimated to grow at a CAGR of over 9.5% from 2023 to 2032. Driven by the surging occurrence of chronic disorders worldwide.
Anticoagulants Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Rising prevalence of chronic disorders such as deep vein thrombosis, and cardiovascular diseases which lead to blood clot formation has increased the need for anticoagulants. As per CDC, although the precise number of people diagnosed with deep vein thrombosis remains obscure, the condition can affect around 900,000 people every year in the U.S. alone. Moreover, the rising adoption of novel oral anticoagulants (NOACs) will further create a plethora of opportunities for market expansion. Benefits such as the rapid onset action, shorter half-life, and predictable pharmacokinetic action, have bolstered the adoption of NOACs.
COVID-19 Impact
The COVID-19 pandemic had a moderate impact on the anticoagulants market owing to supply chain disruptions caused by prolonged lockdowns. However, the surging prevalence of venous thromboembolism that led to blood clots in the veins of COVID-19 patients increased product uptake. For instance, in January 2021, WHO rolled-out a recommendation stating patients diagnosed with COVID-19, including confirmed and suspected cases, should have access to follow-up care with low-dose anticoagulants.
Anticoagulants Market Trends
Recent breakthroughs in genetic testing and pharmacogenomics will positively impact the industry landscape through 2032. These advancements have paved the way for personalized medicine approaches in anticoagulation therapy. Genetic variations can influence an individual's response to anticoagulant medications, including the risk of bleeding or thrombotic events. Tailoring the choice and dosing of anticoagulants based on a patient's genetic profile can significantly improve treatment outcomes and reduce adverse events.
Anticoagulants Market Analysis
Based on the drug category, the anticoagulants market revenue from the Factor Xa inhibitor segment will reach USD 58.4 billion by 2032. High availability of Factor Xa inhibitors globally is contributing to segment growth. These drugs can lower the risk of stroke and venous thrombosis. Additionally, people taking them do not require frequent blood tests.
With respect to application, the anticoagulants market from coronary heart disease segment was worth over USD 21.8 billion in 2022. Growing prevalence of coronary heart disease attributed to the surging adoption of a sedentary lifestyle has increased the need for anticoagulants. As per the National Institutes of Health, coronary artery disease affects around 18.2 million American adults, making it the most common heart disease in the U.S. In addition, surging elderly population that is highly susceptible to this disorder will further increase product uptake.
North America held approximately 60.5% of the anticoagulants market share in 2022. Growing healthcare spending in the region is positively impacting industry landscape. Moreover, the rising burden of cardiovascular disorders has further increased the need for anticoagulants in the region. North America is also home to major industry players such as Johnson and Johnson, Pfizer, and others focusing on product innovations to extend their footprint.
Anticoagulants Market Share
Anticoagulants Industry News:
This anticoagulants market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Million & Tons) from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Drug Category
By Route of Administration
By Application
By Distribution Channel
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →